AstraZeneca Imfinzi Shows Improved Durable Responses In Extensivestage SCLC

AstraZeneca: Imfinzi Shows Improved, Durable Responses In Extensive-stage SCLC

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) said Imfinzi (durvalumab) significantly improved overall survival in patients with previously-untreated extensive-stage small cell lung cancer. The deta...

More From BioPortfolio on "AstraZeneca: Imfinzi Shows Improved, Durable Responses In Extensive-stage SCLC"